Strongbridge Biopharma plc Added to the Russell 3000® Index
June 26 2017 - 7:30AM
Strongbridge Biopharma plc (NASDAQ:SBBP), a global commercial-stage
biopharmaceutical company focused on the development and
commercialization of therapies for rare diseases with significant
unmet needs, today announced that it has been added to the
broad-market Russell 3000® Index, which includes the small-cap
Russell 2000® index, at the conclusion of the Russell indexes
annual reconstitution, effective after the U.S. market opens on
June 26, 2017.
Annual Russell indexes reconstitution captures
the 4,000 largest U.S. stocks as of the end of May, ranking them by
total market capitalization. Membership in the U.S. all-cap Russell
3000® Index allows for automatic inclusion in the large-cap Russell
1000® Index or small-cap Russell 2000® Index. FTSE Russell
determines membership for its Russell indexes primarily by
objective, market-capitalization rankings and style attributes.
Russell indexes are widely used by investment
managers and institutional investors for index funds and as
benchmarks for active investment strategies. Approximately $8.4
trillion in assets are benchmarked against Russell’s U.S. indexes.
Russell indexes are part of FTSE Russell, a leading global index
provider.
For more information on the Russell 3000® Index
and the Russell indexes reconstitution, visit the “Russell
Reconstitution” section on the FTSE Russell website.
About Strongbridge
Biopharma Strongbridge
Biopharma is a global commercial-stage biopharmaceutical
company focused on the development and commercialization of
therapies for rare diseases with significant unmet needs.
Strongbridge's first commercial product is KEVEYIS®
(dichlorphenamide), the first and only FDA-approved treatment
for hyperkalemic, hypokalemic, and related variants of Primary
Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in
the U.S. through August 7, 2022. In addition to establishing
this neuromuscular disease franchise, the Company has a
clinical-stage pipeline of therapies for rare endocrine diseases.
Strongbridge's lead compounds include
RECORLEV™ (levoketoconazole), a cortisol
synthesis inhibitor currently being studied for the treatment of
endogenous Cushing's syndrome, and veldoreotide, a next-generation
somatostatin analog being investigated for the treatment of
acromegaly, with potential additional applications in Cushing's
syndrome and neuroendocrine tumors. Both RECORLEV and veldoreotide
have received orphan designation from the U.S. Food and Drug
Administration and the European Medicines Agency. For
more information, visit www.strongbridgebio.com.
Contacts:
Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com
Investor Relations
US:
The Trout Group
Marcy Nanus
+1 646-378-2927
mnanus@troutgroup.com
Europe:
First House
Mitra Hagen Negård
+47 21 04 62 19
strongbridgebio@firsthouse.no
USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610-254-9200
Fax. +1 215-355-7389
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Sep 2023 to Sep 2024